Provided herein are systems, apparatuses, and methods for localized, on-demand diesel exhaust fluid (“DEF”) production. The systems can comprise a loading station for securing a container comprising a pre-measured quantity of urea and releasing the urea from the container. The released urea and water can then be fed into a mixing tank to produce the DEF product. The water can be pre-treated, for example, in a reverse osmosis and/or deionization process before being fed to the mixing tank. The DEF product can be immediately dispensed into a diesel vehicle or stored in a nearby intermediate storage tank. The systems and processes advantageously reduce or eliminate the need for over-the-road shipments and retail packaging of DEF.

The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.

A production system for a product selected from a nitrogen-containing product and a fermented and cultured product that does not involve (or can minimize) the transport of liquid ammonia can include: an ammonia synthesis apparatus in which an ammonia-containing gas is synthesized by reaction of a source gas containing hydrogen and nitrogen in the presence of a supported metal catalyst containing as a support one or more selected from the group consisting of: i) a conductive mayenite compound; ii) a two-dimensional electride compound or a precursor thereof; and iii) a complex formed of a support base containing at least one metal oxide selected from ZrO.sub.2, TiO.sub.2, CeO.sub.2, and MgO and a metal amide represented by a formula M(NH.sub.2).sub.x (where M represents one or more selected from Li, Na, K, Be, Mg, Ca, Sr, Ba, and Eu; and x represents a valence number of M) supported by the support base.

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection. ##STR00001##

The present invention relates to a method for the synthesis of cyclic depsipeptides, in particular emodepside, from the open form.

The present invention regards a process for the production of an aqueous solution comprising urea for use in the removal of nitrogen oxides from combustion gas or fumes, the process being characterized in that it comprises the steps of: subjecting at least a part of a urea-concentrated aqueous solution comprising residual free ammonia, obtained directly from or downstream of a recovery section of a plant for the production of urea, to washing with carbon dioxide, so obtaining a first vapor phase comprising carbon dioxide and optionally ammonia and a urea-concentrated aqueous solution comprising carbamate and essentially lacking in free ammonia, and diluting said urea-concentrated aqueous solution comprising carbamate and essentially lacking in free ammonia with water until the desired concentration of urea in aqueous solution is reached.

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

##STR00001##

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

##STR00001##

A method for continuously preparing biuret polyisocyanate, comprising: a mixed solution of a diisocyanate and a catalyst with water vapour, in an aerosol form, are continuously reacted in a first reactor; the product obtained therefrom is brought into a second reactor for a further reaction; a tail gas from the second reactor is condensed and refluxed, and the non-condensable gas is brought into a tail gas treatment system; a reaction liquid obtained in the second reactor is further reacted in a third reactor; and then separation is performed for removing monomers, so as to obtain biuret polyisocyanate.